Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.200
-0.160-0.63%
Volume:7.14M
Turnover:180.29M
Market Cap:21.97B
PE:73.36
High:25.640
Open:25.300
Low:24.940
Close:25.360
52wk High:34.800
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.70
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:2.30
PE(LYR):73.36
PS:4.69

Loading ...

Hong Kong Stock Movement | Innovative Drug Stocks Rise Across the Board as 2025 World Lung Cancer Congress Approaches, Institutions Bullish on Valuation Recovery Potential of Innovative Drug Sector

Stock News
·
Sep 05

Hong Kong Stock Movement | HUTCHMED (00013) Surges Over 5% as Company to Present Latest Data on Self-Developed Compounds at 2025 WCLC and CSCO Conferences

Stock News
·
Sep 05

HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference

Stock News
·
Sep 05

HUTCHMED Announces Presentation of New Clinical Data on Savolitinib at 2025 World Conference on Lung Cancer

Reuters
·
Sep 05

Hong Kong Stock Movement | Innovative Drug Concept Stocks See Expanding Declines as Trump Announces Swift Pharmaceutical Tariffs, Morgan Stanley Expects Low Likelihood of BD Taxation

Stock News
·
Aug 26

Hutchmed Names Johnny Cheng Acting CEO

MT Newswires Live
·
Aug 25

Hutchmed Names CFO as Acting CEO

MT Newswires Live
·
Aug 25

BRIEF-Hutchmed (China) Says Weiguo Su Takes Leave As CEO Due To Health Reasons

Reuters
·
Aug 25

HUTCHMED (00013): Executive Director and CFO Zheng Zefeng Appointed as Interim CEO

Stock News
·
Aug 25

HUTCHMED (China) Ltd - Weiguo SU Takes Leave as CEO Due to Health Reasons

THOMSON REUTERS
·
Aug 25

HUTCHMED (China) Ltd - Johnny Cheng Appointed Acting CEO of HUTCHMED

THOMSON REUTERS
·
Aug 25

Press Release: HUTCHMED Announces Appointment of Acting Chief Executive Officer

Dow Jones
·
Aug 25

Hutchmed Completes Patient Enrollment in Phase 3 Study of Lung Cancer Combination Treatment

MT Newswires Live
·
Aug 20

HUTCHMED (00013) Completes Patient Enrollment for SANOVO China Phase III Study Evaluating ORPATHYS® and TAGRISSO® Combination Therapy for First-Line Treatment of Specific Lung Cancer Patients

Stock News
·
Aug 20

HUTCHMED Completes Patient Enrollment of Sanovo Phase Iii Trial of Orpathys® and Tagrisso® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

THOMSON REUTERS
·
Aug 20

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

GlobeNewswire
·
Aug 20

Master Tec Group Malaysia 2nd-Quarter 2025 Earnings Summary Table

Dow Jones
·
Aug 11

HK Movers | HUTCHMED Collapses 14% After Rev. Slides; ZAI LAB Tumbles over 11% 2Q Rev. Growth Misses

Tiger Newspress
·
Aug 08

Stock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors

Stock Track
·
Aug 08

BRIEF-Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M

Reuters
·
Aug 07